Navigation Links
NYU study reveals how brain's immune system fights viral encephalitis

New York University biologists have uncovered how the innate immune system in mice's brains fights viral infection of neurons. The findings, published as the cover study in the latest issue of Virology, show that proteins in neurons fight the virus at multiple stages--by preventing the formation of viral RNA and proteins, and blocking the virus' release, which could infect other cells in the brain.

"There is no magic bullet in fighting viral infections in neurons," said NYU Biology Professor Carol Shoshkes Reiss, the study's senior author. "However, these findings show the redundancy of the immune system--when one response fails to fight infection, others step in."

The study was also conducted at NYU, by a post-doctoral fellow, Mark Trottier, Jr., PhD, now at Michigan State, and Beth Palian, currently a doctoral student at the University of Southern California.

Recently, the West Nile virus has been responsible for a viral encephalitis outbreak in the northeast. The NYU researchers set out to determine how the body can fight viral encephalitis. Specifically, they examined how type I interferons--proteins made by the body that are released in response to stimuli, notably infection--work in neurons and to determine if nerve cells' response to interferons is similar to that of other cells.

Examining the effect of the virus in mice and in cell culture, the researchers found that neurons are sensitive to the protective effect of interferons, inducing pathways to fight the virus' spread. However, their findings showed that interferons fight the virus at different stages of the virus' life cycle. First, they inhibit viral RNA and protein synthesis. If this fails, interferons block the virus from forming particles which can be released and infect other neurons. This is critical, since the immune system does not kill infected precious neurons the way it does other cells, which can be replaced.

The researchers attributed the spread of vi ral encephalitis to the inability of lab mice to produce sufficient amounts of interferons to fight the virus.


'"/>

Source:New York University


Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. Loves all in the brain: fMRI study shows strong, lateralized reward, not sex, drive
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... , March 2, 2017 Summary ... to better understand Merck KGaA and its partnering interests ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , ... software globally, announces significant enhancements to new and core ... 2016. New products include mobile and desktop Acuant FRM ... TM - a real time manual review of ... idScan® technology provides the fastest and most accurate capture ...
(Date:2/26/2017)... DALLAS , Feb. 25, 2017  Securus ... justice technology solutions for public safety, investigation, corrections ... of Recidivism and Reentry. "Too often, ... State prisons and county jails are trying to ... of inmates and friends and family members. While significant ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused on ... today that Dr. Miriam Kidron , Oramed,s ... "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock," ... Peptide Therapeutics (OPT) Boston Conference in Cambridge, ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
(Date:3/22/2017)... ... , ... Okyanos Cell Therapy has announced Tallahassee, FL will be the next ... Cell Therapy: The Next Phase in the Evolution of Medicine.” As the Bahamas’ first ... Therapy Act, Okyanos maintains a mission to help “no-option” patients and those with ...
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced the launch ... held on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The CMO ... Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces a unique ...
Breaking Biology Technology: